Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TRMT1 CRISPR/Cas9 KO Plasmid (h): sc-410018
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TRMT1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TRMT1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TRMT1 Antibody (G-3): sc-373687
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRMT1 CRISPR/Cas9 KO Plasmid (h) | sc-410018 | 20 µg | $397.00 |
Overview
TRMT1 encodes tRNA methyltransferase 1, an RNA-modifying enzyme that catalyzes N2,N2-dimethylguanosine (m2,2G) formation at position 26 in multiple cytosolic tRNAs. This modification supports proper tRNA folding and decoding accuracy, thereby influencing global translational efficiency and proteostasis. TRMT1 activity links RNA epitranscriptomic regulation to cellular stress responses, with downstream effects on protein synthesis programs during growth and differentiation. Altered TRMT1 function has been associated with neurodevelopmental phenotypes, making it a useful target for dissecting how tRNA modification dynamics shape neuronal and stress-adaptive gene expression.
TRMT1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TRMT1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TRMT1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TRMT1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TRMT1 protein expression.
This CRISPR knockout system enables efficient generation of TRMT1-deficient cell models for investigation of TRMT1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TRMT1 exon(s) critical for TRMT1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TRMT1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TRMT1 CRISPR/Cas9 KO Plasmid (h) and TRMT1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TRMT1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TRMT1 HDR Plasmid (h) and TRMT1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TRMT1 homology arms to support homology-directed repair at defined TRMT1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.